ArticleWorld journal of surgical oncology2026
LncRNA ACTA2-AS1 acts as a bladder cancer prognostic biomarker and blocks malignant advance via miR-148b-3p/DNAJB4.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong non-coding RNA (lncRNA) is crucial in bladder cancer (BCa) development. This research explores the clinical significance and underlying mechanisms of lncRNA ACTA2-AS1 in BCa.
methodsFrom the GEO database, differentially expressed lncRNAs (DElncRNAs) in BCa were identified, and tumor, along with adjacent non-tumor tissue samples from 132 patients, were collected. RT-qPCR was employed for the quantitative measurement of ACTA2-AS1, miR-148b-3p, and DNAJB4 expression. Chi-square analysis was employed to assess the association of ACTA2-AS1 with clinical features. Kaplan-Meier and Cox regression evaluated ACTA2-AS1's prognostic value. CCK-8, Transwell, and flow cytometry assays evaluated cell proliferation, migration, invasion, apoptosis, and cell cycle arrest. DLR and RIP tests confirmed miR-148b-3p's targeting of ACTA2-AS1 and DNAJB4.
resultsACTA2-AS1 showed significant downregulation in four GEO databases. Moreover, both ACTA2-AS1 and DNAJB4 were notably decreased in BCa tumor tissues, while miR-148b-3p increased significantly. Low ACTA2-AS1 expression correlates with poor tumor differentiation, positive lymph node metastasis, and TNM stage III-IV. Moreover, patients with low ACTA2-AS1 expression are associated with a significantly unfavorable prognosis. Mechanistically, miR-148b-3p targets ACTA2-AS1 and DNAJB4. The suppression impacts of ACTA2-AS1 on BCa cell proliferation, migration, and invasion, and its boost of apoptosis and cell cycle arrest were greatly reversed by miR-148b-3p.
conclusionLow ACTA2-AS1 expression is a potential biomarker for unfavorable prognosis in BCa patients. Furthermore, ACTA2-AS1 may counteract BCa's malignant biological behaviors via targeting the miR-148b-3p/DNAJB4 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.